Clinical Outcomes Related to Treatment of Distal Symmetric Polyneuropathy Using Semiconduc
Distal symmetric polyneuropathy, also known as diabetic neuropathy, is the most common neurological complication of diabetes and a main cause of morbidity. The condition leads to gradual loss of function of the longest nerve fibers that limits function and decreases quality of life. Symptoms present distally and symmet
| Condition(s) | Diabetic Neuropathy |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Distal symmetric polyneuropathy, also known as diabetic neuropathy, is the most common neurological complication of diabetes and a main cause of morbidity. The condition leads to gradual loss of function of the longest nerve fibers that limits function and decreases quality of life. Symptoms present distally and symmetrically in toes and feet. Symptoms of the neurologic disability include sensory loss, risk of foot ulcers and limb amputations and pain. The condition is not generally considered reversible, and condition management aims to slow progression and prevent complications. According to estimates from the International Diabetes Federation, diabetic neuropathy affected approximately 425 million people in 2017, with projections indicating a rise to 628 million by 2045. Despite the hig |
| Who can participate | Inclusion Criteria: * Patients diagnosed with mild to moderate Diabetic Neuropathy with a score between 2 and 7 out of 10 on the MNSI upon clinical examination and assessment. * Patients reporting symptoms of Diabetic Neuropathy * Patients age 18-79 * Patients who are willing and able to adhere to follow-up schedule and protocol guidelines * Patients who are willing and able to sign corresponding research subject consent form Exclusion Criteria: * Patient has a history of neurodegenerative conditions, including multiple sclerosis or Parkinson's disease * Patient has chronic pain conditions unrelated to diabetic neuropathy, including spinal stenosis, low back pain, and sciatica * Patient has auto-immune or auto-inflammatory diseases other than Diabetic Neuropathy, including Multiple Scleros |
| Ages | 18 Years to 79 Years |
| Sex | All |
| Lead sponsor | Endocrine Research Solutions |
| Locations | Roswell, Georgia, United States |
| Start date | 2024-06-11 |
| NCT ID | NCT06452914 |
| Official listing | https://clinicaltrials.gov/study/NCT06452914 |